Research

Holowatyj receives National Cancer Institute MERIT Award

Vanderbilt’s Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

Alzheimer’s genetic risk tracked across sex, race

A Vanderbilt study of genetic risks for cognitive impairment later in life uses data from 32,426 research participants ages 60 and older to elaborate these risks across sex and across the intersection of sex and race.

Study uses statistical and population-based methods to understand comorbidities of developmental language disorder

A recent Vanderbilt study is one of the first to use statistical and population-based methods to understand comorbidities associated with developmental language disorder at a population level.

Julie Hudson, MD, far left left, and Billy Hudson, PhD, far right, with this year's cohort of 19 high school students from eight states who participated in the summer research program at VUMC. (photo by Susan Urmy)

Aspirnaut scientific symposium set for Friday, July 14

The Vanderbilt University Medical Center community is invited to attend a scientific symposium on Friday, July 14, presented by high school participants in the Aspirnaut K-20 STEM pipeline for diversity and wellness.

Novel treatments for fake patients

A customizable framework uses simulated patients to distinguish effects of a new treatment from “learning effects” for clinicians; it should help identify training opportunities and hasten treatment improvements.

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

1 30 31 32 33 34 136